Evidence map›Paper›PMID 32421775›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.

Petra J Woestenberg, Alejandra E Guevara Morel, Johannes A Bogaards, Mariëtte Hooiveld, Tessa M Schurink-van 't Klooster, Christian J P A Hoebe, Marianne A B van der Sande, Birgit H B van Benthem

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Petra J WoestenbergCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.ORCID 0000-0003-1010-7373
Alejandra E Guevara MorelDepartment of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Johannes A BogaardsCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Mariëtte HooiveldNivel, Utrecht, The Netherlands.
Tessa M Schurink-van 't KloosterCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Christian J P A HoebeCare and Public Health Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands.
Marianne A B van der SandeDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Birgit H B van BenthemCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NLMaastricht University · NLNetherlands Institute for Health Services Research · NLUniversity Medical Center Utrecht · NLVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is ongoing debate about the possible protective effect of the bivalent human papillomavirus (2vHPV) vaccine, targeting oncogenic types HPV-16/18, against anogenital warts (AGWs), commonly attributed to HPV-6/11. We performed a retrospective registry-based open cohort study to assess the effect of 2vHPV vaccination on AGWs.

methodsWe linked general practice (ie, primary care) data from women born between 1993 and 2002, who had been eligible for HPV vaccination in the Netherlands, to the Dutch national immunization registry on an individual level. Women were followed until their first AGW diagnosis or end of follow-up. Adjusted incidence rate ratios (aIRRs) were estimated using Poisson regression with vaccination status as a time-dependent exposure.

resultsWe linked data of 96 468 women with a total of 328 019 years observation time and 613 AGW diagnoses (incidence: 1.87/1000 person-years). At the end of follow-up, 61% were 2vHPV vaccinated (≥ 1 dose) of whom 91% were fully vaccinated. The AGW incidence was lower among those with ≥ 1 dose vs 0 doses (aIRR, 0.75 [95% confidence interval {CI}, .64-.88]). The effect of vaccination was stronger after full vaccination (aIRR, 0.72 [95% CI, .61-.86]) and for women who were offered vaccination at 12-13 years of age (aIRR, 0.69 [95% CI, .51-.93]) vs those at 13-16 years of age (aIRR, 0.77 [95% CI, .64-.93]).

conclusionsThis is the largest population-based study so far to examine the effect of 2vHPV vaccination on AGWs, with reliable individual information on AGW diagnoses and vaccination status. The results indicate that 2vHPV vaccination partially protects against AGWs, especially when administered in early adolescence.

Indexed as

Condylomata AcuminataPapillomavirus InfectionsPapillomavirus VaccinesAdolescentCohort StudiesFemaleHuman papillomavirus 16Human papillomavirus 18HumansNetherlandsPrimary Health CareRetrospective StudiesVaccinationPapillomavirus Vaccinesanogenital wartsbivalent HPV vaccinecross-protectionhuman papillomavirusvaccine effectiveness

Identifiers

PMID32421775
PMCPMC8516515
OpenAlexW3027549326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.